| Latest Forum Topics / Trendlines Last:0.052 -- |
 Post Reply
|
|
Dasin Retail Trust
|
|||||||||||||||||||||||||
|
eric998
Supreme |
05-May-2026 10:16
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
BBs try 70s series? Trade with care. | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
Joelton
Supreme |
05-May-2026 10:16
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trial The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe. According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners. Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines. &ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva. &ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines. Shares in Trendlines closed flat at 6.2 cents on May 4. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
|
SmallSmall
Supreme |
05-May-2026 08:15
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trialThe study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Photo: Bloomberg
The Trendlines Group Trendlines announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe. According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners. Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines. &ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva. &ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
JAMMIE
Senior |
04-May-2026 19:44
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Imagine when as a chocolate manufacturer you have control over price of cocoa, control over production, control over not needing to rely on expensive transport, etc. basivally it will lead to predicatble cost in your supply chain and this will lead to higher productivity and profits. just one scenario. This ofcourse will bot replace the supply of natural cocoa in the medium term but in the long term the implications can be huge.
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
SmallSmall
Supreme |
04-May-2026 18:54
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
The Trendlines Group&rsquo s Company Vensica Medical Advances Needle-Free Bladder Therapy to Phase 2 &bull Vensica received FDA IND clearance to initiate Phase 2 study of ViXe, its needle-free Xeomin® delivery system for overactive bladder. &bull Strategic milestone validates clinical rationale for needle-free delivery and triggers milestone payment from strategic partners. &bull ViXe aims to transform the standard of care for 33 million Americans living with overactive bladder through a non-invasive ultrasound-based solution. &bull The Group holds approximately 9% in Vensica, founded by Avner Geva and incubated by Trendlines. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
|
bechaotic
Member |
22-Apr-2026 11:55
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
This chocolate-cultured bar - how will it affect other chocolate manufacturers like Delfi Ltd? |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
Joelton
Supreme |
22-Apr-2026 11:48
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Trendlines portfolio company Celleste Bio introduces world&rsquo s first milk chocolate bars with cell-cultured cocoa butter The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Celleste Bio, successfully produce the world&rsquo s first milk chocolate bars made with real cocoa butter using cell suspension culture technology. Major multinational snack company, Mondelē z International, used the cocoa butter from Celleste Bio to produce almost 12 chocolate bars that met its product standards. According to Trendlines, Celleste Bio intends to transform the chocolate market by using AI modelling to tailor cocoa butter for specific melting points and flavour profiles, giving manufacturers a boost in innovation and competitiveness. Meanwhile, Celleste Bio is developing a resilient supply chain by achieving commercial-scale cocoa butter production in a 1000-liter bioreactor using only a single cocoa bean. Trendlines claims that this process eliminates the sole dependence on the traditional farming of cocoa trees and supplements production, without replacing it. &ldquo This milestone demonstrates Celleste Bio' s cell cultured ingredients are bio-identical to conventionally grown cocoa - meaning they deliver the same texture, melt profile and sensory experience, and sets the stage for scaling production to market-ready quantities in the foreseeable future,&rdquo says Haim Brosh, Trendlines&rsquo CEO. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
eric998
Supreme |
22-Apr-2026 11:29
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Dare to put the sell queues means there will be BBs dare to clear. Retailers if can?t keep better stay away. Trade with care.
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
|
newbie1118
Master |
22-Apr-2026 11:12
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
The buy queue can be fake queue. Pretty scary. | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
newbie1118
Master |
22-Apr-2026 10:56
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Seems like game over.
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
eric998
Supreme |
22-Apr-2026 10:35
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Near lunch or after lunch? Today 70s series?
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
newbie1118
Master |
22-Apr-2026 10:07
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Short squeeze later? | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
|
eric998
Supreme |
22-Apr-2026 10:05
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
70 series coming? | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
SmallSmall
Supreme |
22-Apr-2026 09:08
|
||||||||||||||||||||||||
|
x 0
x 1 Alert Admin |
TRENDLINES' s World First: Chocolate Made With Cocoa Butter From a Lab22 April 2026
Celleste Bio uses proprietary cell suspension culture technology. In simple terms, cells from a high-quality cocoa bean are grown in a controlled environment.
Celleste can produce enough chocolate-grade cocoa butter for chocolate bars using only a single cocoa bean. The Trendlines press release says Celleste intends to " transform the chocolate market by using AI modelling to tailor cocoa butter for specific melting points and flavour profiles" . Over the past three years, Celleste has validated its cultured cocoa butter as a direct alternative, and established a pilot facility for scaling production. In a show of confidence, Mondelē z International, the maker of Cadbury and Toblerone, acted as a strategic and design partner, using Celleste&rsquo s cocoa butter to produce almost 12 chocolate bars that met its rigorous product standards.
Traditional cocoa farming will come under pressure. Celleste&rsquo s technology introduces a resilient supply chain by achieving commercial-scale production in a 1,000-liter bioreactor using a single cocoa bean. This process " eliminates the sole dependence on the traditional farming of cocoa trees and supplements production, without replacing it," says Trendlines. By moving production to controlled facilities, the industry can create a buffer against the sharp price spikes we see when traditional harvests fail. Will chocolates get cheaper? It' s too early to tell. With market-ready cultured cocoa butter anticipated by 2027, the goal is commercial viability. Because cell-cultured cocoa isn' t dependent on the weather, it offers a way to bypass the supply shocks that drive up the price of chocolates. For chocolate makers, this is a game-changer. Manufacturers can now access a replacement that " preserves the quality and functionality that chocolate makers and consumers depend on" .
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
Stocky901
Supreme |
22-Apr-2026 09:04
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Lai liao.. don't short? 🤔 | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
SmallSmall
Supreme |
22-Apr-2026 08:33
|
||||||||||||||||||||||||
|
x 0
x 1 Alert Admin |
For info Mondele z International owns Cadbury. So that itself speaks volume
|
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
SmallSmall
Supreme |
21-Apr-2026 17:34
|
||||||||||||||||||||||||
|
x 0
x 2 Alert Admin |
Mondelē z International has used Celleste Bio&rsquo s cell-based cocoa butter to create nearly a dozen milk chocolate bars, a milestone moment for the cellular agriculture industry.Cell-based chocolate is no longer a pipe dream &ndash and one of the world&rsquo s largest confectionery companies is leading the charge. Mondelē z International has developed nearly a dozen milk chocolate bars with cell-based cocoa butter from Israeli startup Celleste Bio, in which the Cadbury owner has been an investor since 2022. Celleste Bio develops the fat using real cocoa cells grown in suspension in a bioreactor. The process takes one to two beans to produce the same amount of cocoa butter that traditionally requires four tonnes of cocoa and 10,000 sq m of land. The Mondelē z innovation is proof that its technology works at scale and meets the consumption standards of an industry giant. Celleste Bio said it sets the stage for scaling up production to market-ready quantities within the next two years. &ldquo It delivers the same texture, melt, and experience as conventional cocoa &ndash and marks a real step toward scalable, commercially viable production,&rdquo CEO Michal Beressi Golomb said in a LinkedIn post. Celleste Bio&rsquo s AI-led process can create customised cocoa butter Courtesy: Celleste Bio Founded in 2022 by Hanne Volpin, Orna Harel, Avishay Levy and Daphna Michaeli, with support from The Trendlines Group, Celleste Bio pairs agtech and biotech with computational artificial intelligence (AI) to produce cocoa ingredients via cell culture. It selects different varieties of cocoa beans, extracts their cells, and grows them in a bioreactor with vitamins, minerals, water and sugar. This then becomes a biomass, from which it extracts cocoa butter and powder. The process is similar to cocoa production in nature, but in a controlled setting under optimal conditions. Importantly, the cells keep growing after the biomass is removed, so the process repeats without needing another bean. The company says its AI-led model is designed to customise cocoa butter to its clients&rsquo specifications, such as higher melting points and taste experiences, which can allow them to level up their innovation and competitive advantage. &ldquo Celleste launched in 2022 with the mission to secure a sustainable future for the global chocolate industry amidst increasing supply chain pressures of climate change, disease, traceability and geopolitical instability,&rdquo said Beressi Golomb. &ldquo In three years, we&rsquo ve made unprecedented progress to meet this formidable scientific challenge. We&rsquo ve validated our ingredients as drop-in replacements, created an operational R& D pilot facility to scale up our volumes and now proven our cocoa butter performs identically to conventional cocoa, clearing the next phase to commercial scale.&rdquo Celleste Bio aims to be market-ready by 2027 Courtesy: Celleste Bio According to Celleste Bio, chocolate manufacturers spend about $16B on cocoa ingredients each year, and cocoa butter alone accounts for nearly half of that. And althouth crop yields and prices can level out at times, long-term instability is almost a given without tech-forward solutions. And instability is exactly what has plagued the cocoa industry. Climate change pushed cocoa stocks to their lowest levels in a decade and prices to all-time highs in 2024. Extreme weather and crop diseases have hit plantations hardest in the Ivory Coast and Ghana, the two largest cocoa producers, which have already lost over 85% of their forest cover since 1960. Scientists warn that a third of the world&rsquo s cocoa trees could die out by 2050. Plus, producing chocolate emits more greenhouse gases than any other food except beef, and the industry is linked to widespread tropical deforestation. &ldquo Building a resilient supply chain means being able to produce at commercial volumes while offsetting disruptions caused by climate change, deforestation and resource scarcity,&rdquo said Celleste Bio&rsquo s chief science and technology officer, Hanne Volpin. &ldquo We are on track to produce one tonne of cocoa butter annually in a 1000-litre bioreactor from a single bean &ndash which would otherwise require about a hectare of cocoa trees. To that end, we&rsquo ve curated a very robust bank of multiple cocoa bean varietals we can use to grow, test and scale material without ever having to cut down a single tree in the rainforest.&rdquo Speaking to Green Queen in October, Beressi Golomb revealed that the company is finalising its pilot facility and anticipates being market-ready by 2027. It&rsquo s currently awaiting approval in the US, the UK, the EU, and Israel. &ldquo The ingredient is and must be at parity with cocoa prices, ideally more cost-efficient when traditional cocoa supply is skyrocketing,&rdquo she said at the time. &ldquo We have two parts of the business: a drop-in replacement, which will be more on par with market costs and premium cocoa, which will be priced for the premium market.&rdquo The startup has already raised $5.6M to date, and is one of several cell-based cocoa innovators being backed by Big Chocolate. Sparkalis, the VC arm of Belgian confectionery giant Puratos, has been an investor in California Cultured from an early stage, and intends to make a cell-based chocolate product available to its clients by the end of the year. Puratos and Lindt are also investors in Switzerland&rsquo s Food Brewer, and Cargill is working on applications with fellow Israeli startup Kokomodo. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
SmallSmall
Supreme |
21-Apr-2026 17:14
|
||||||||||||||||||||||||
|
x 0
x 2 Alert Admin |
Unfortunately no matching price. If not can buy now Trendlines Portfolio Company Celleste Bio&trade Unveils World' s First Milk Chocolate Bars Made with Cell Cultured Cocoa Butter &bull This achievement positions Celleste to scale its operations, with market-ready cell cultured cocoa butter anticipated by 2027. &bull Founded and incubated by Trendlines, Trendlines holds a 17% stake in Celleste Misgav, Israel &ndash 21 April 2026 &ndash The Trendlines Group Ltd. (SGX: 42T OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, is thrilled to announce that portfolio company Celleste Bio&trade (&ldquo Celleste&rdquo ) unveiled the world' s first milk chocolate bars made with real cocoa butter using cell suspension culture technology. This marks a significant advancement for Celleste in accelerating its ability to build a scalable and commercially viable cocoa supply. Mondelē z International used the cocoa butter from Celleste to produce almost twelve chocolate bars that met its product standards. Celleste can produce enough chocolate grade cell cultured cocoa butter for chocolate bars using only a single cocoa bean. Celleste, founded in 2022, has over the past three years achieved significant milestones, including validating its cell cultured cocoa butter as a direct alternative to traditional cocoa, establishing a pilot facility for scaling production, and demonstrating that its product matches the quality and performance of conventional cocoa butter. These accomplishments have positioned Celleste to move toward commercial-scale operations. Celleste intends to transform the chocolate market by using AI modelling to tailor cocoa butter for specific melting points and flavour profiles, giving manufacturers a boost in innovation and competitiveness. Celleste is developing a resilient supply chain by achieving commercial-scale cocoa butter production in a 1000-liter bioreactor using only a single cocoa bean. This process eliminates the sole dependence on the traditional farming of cocoa trees and supplements production, without replacing it. Celleste has established a diverse bank of cocoa bean varieties for testing and scaling production, ensuring sustainable growth without harming natural resources. To date, Celleste has raised US$5.6 million from various investors, including Mondelē z International as a strategic and design partner, along with The Trendlines Group, Supply Change Capital, Barrel Ventures, Consensus Business Group and other non-dilutive grants. Trendlines&rsquo Executive Director and CEO Haim Brosh commented, &ldquo This milestone demonstrates Celleste' s cell cultured ingredients are bio-identical to conventionally grown cocoa - meaning they deliver the same texture, melt profile and sensory experience, and sets the stage for scaling production to market-ready quantities in the foreseeable future. |
||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
newbie1118
Master |
14-Apr-2026 14:56
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Finally waking up? | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
|
newbie1118
Master |
14-Apr-2026 12:05
|
||||||||||||||||||||||||
|
x 0
x 0 Alert Admin |
Accumulate when everybody is scared. | ||||||||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||||||||
" This milestone demonstrates Celleste' s cell cultured ingredients are bio-identical to conventionally grown cocoa - meaning they deliver the same texture, melt profile and sensory experience, and sets the stage for scaling production to market-ready quantities in the foreseeable future."